Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell LymphomaElise A. Olsen, Jean Nichols, Arturo Molina et al.|Journal of Clinical Oncology|2001Cited by 610
Epstein-Barr Virus As a Marker of Survival After Hodgkin's Lymphoma: A Population-Based StudyTheresa H.M. Keegan, Richard F. Ambinder, Sally L. Glaser et al.|Journal of Clinical Oncology|2005Cited by 168
Guidelines for Interpreting EBER In Situ Hybridization and LMP1 Immunohistochemical Tests for Detecting Epstein-Barr Virus in Hodgkin LymphomaMargaret L. Gulley, Richard F. Ambinder, Sally L. Glaser et al.|American Journal of Clinical Pathology|2002Cited by 163
Population‐based patterns of human immunodeficiency virus‐related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988–1998Sally L. Glaser, Richard F. Ambinder, Christina A. Clarke et al.|Cancer|2003Cited by 107
Racial/ethnic variation in EBV‐positive classical Hodgkin lymphoma in California populationsSally L. Glaser, Richard F. Ambinder, Margaret L. Gulley et al.|International Journal of Cancer|2008Cited by 63